Compugen Ltd expands collaboration agreement with Bristol Myers Squibb with phase 1b combination study of COM701 with opdivo C... Feb 22
Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today declared their 4th and full year report.... Feb 21
-Advertisements-